Product Details
Product Name:
ACBI1 |
CAS No.:
2375564-55-7 |
Purity:
98.15% |
Supply Ability:
10g |
Release date:
2024/11/18 |
Product Introduction
Bioactivity
名稱 | ACBI1 |
描述 | ACBI1 is a potent PROTAC degrader of BAF ATPase subunits SMARCA2 and SMARCA4, also degrades the polybromo-associated BAF (PBAF) complex member PBRM1, with DC50s of 6 nM, 11 nM and 32 nM for SMARCA2, SMARCA4 and PBRM1 in MV-4-11 cells, respectively. ACBI1 is composed of a bromodomain ligand, a linker, and the E3 ubiquitin ligase VHL. ACBI1 can induce anti-proliferative effects and apoptosis. |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 100 mg/mL (106.83 mM)
|
關(guān)鍵字 | PROTACs | anti-proliferative | Epigenetic Reader Domain | ACBI 1 | Inhibitor | ACBI1 | ACBI-1 | Apoptosis | inhibit |
相關(guān)產(chǎn)品 | Stavudine | Sodium 4-phenylbutyrate | Tributyrin |
相關(guān)庫 | 細胞凋亡化合物庫 | 經(jīng)典已知活性庫 | 泛素化化合物庫 | 表觀遺傳庫 | NO PAINS 化合物庫 | PPI抑制劑庫 | 已知活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:174722-31-7
$229.00 / 1mg
-
-
CAS:5654-87-5
$50.00 / 5mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$200.00/100MG |
VIP1Y
|
Hubei Chuchang Biotech Co., Ltd.
|
2024-11-18 |
|
$0.00/100MG |
VIP1Y
|
Hubei Chuchang Biotech Co., Ltd.
|
2024-04-17 |